The inhaler developed by Pneuma Respiratory has successfully demonstrated bronchodilation in clinical tests. In two studies, one using asthma medication and the other using a chronic obstructive pulmonary disease (COPD) treatment, the device adequately delivered small molecules to the lungs. Pre-clinical trials showed the device was capable of administering doses of large, complex molecules intact. If the device proves dependable in delivering a wide range of molecule sizes, it can be used to carry multiple medications to treat different parts of the lungs. A more significant competitive edge of Pneuma Respiratory’s digital soft-mist inhaler is it comes with an app that releases the prescribed dose as the patient inhales, using no propellants. The product’s developers were responding to research indicating patients often do not adopt the proper technique for using their inhalers, and thus do not receive sufficient medication. Not only does the digital respirator deliver proper dosages, it communicates with providers in real time to document the administration. 40 million people who suffer asthma and COPD in the United States stand to benefit from the device. Launched in 2015, Pneuma Respiratory is a global team of researchers with headquarters in Boone, North Carolina.